Table II.
Correlation between CRM-1 and survivin expression in the nucleus and cytoplasm in gastric and colorectal carcinoma.
Nuclear survivin | Cytoplasmic survivin | |||
---|---|---|---|---|
Cancer type | r | P-value | r | P-value |
Gastric carcinoma, total | ||||
N-CRM-1 | 0.484 | <0.001a | 0.322 | 0.008a |
C-CRM-1 | 0.192 | 0.113 | 0.127 | 0.296 |
Gastric carcinoma, intestinal type | ||||
N-CRM-1 | 0.204 | 0.249 | 0.292 | 0.098 |
C-CRM-1 | 0.096 | 0.588 | 0.267 | 0.131 |
Gastric carcinoma, diffuse type | ||||
N-CRM-1 | 0.649 | 0.001a | 0.371 | 0.028a |
C-CRM-1 | 0.245 | 0.147 | 0.078 | 0.645 |
Colorectal carcinoma, total | ||||
N-CRM-1 | 0.338 | 0.003a | 0.299 | 0.009a |
C-CRM-1 | 0.254 | 0.026a | 0.268 | 0.019a |
P<0.05. CRM-1, chromosomal regional maintenance protein-1; N-CRM-1, nuclear CRM-1; C-CRM-1, cytoplasmic CRM-1.